The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma

作者：Heng Ma, Xianlong Chen, Shengwei Mo, Xinxin Mao, Jingci Chen, Yilin Liu, Zhaohui Lu, Shuangni Yu, Jie Chen · 发表于：Theranostics · 年份：2023 · DOI：10.7150/thno.86547 · 被引用次数：12 · 研究领域：Cancer Immunotherapy and Biomarkers、Immune Cell Function and Interaction、Immune cells in cancer

Our findings suggest that targeting TIGIT/CD155 immunosuppressive axis may guide patient stratification and improve the clinical outcome of PDAC.